Merck (MRK) Net Cash Flow (QoQ) (2009 - 2026)
Powered by 
Analysis
Merck (MRK) Net Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 116.50% |
| Mar 31, 2026 | -158.09% |
| Dec 31, 2025 | -135.31% |
| Sep 30, 2025 | 1,085.19% |
| Jun 30, 2025 | 78.22% |
| Mar 31, 2025 | -372.78% |
| Dec 31, 2024 | -133.20% |
| Sep 30, 2024 | -47.77% |
| Jun 30, 2024 | 625.82% |
| Mar 31, 2024 | 43.47% |
| Dec 31, 2023 | -162.49% |
| Sep 30, 2023 | 178.22% |
| Jun 30, 2023 | -29.51% |
| Mar 31, 2023 | -372.52% |
| Dec 31, 2022 | -41.80% |
| Sep 30, 2022 | 33.84% |
| Jun 30, 2022 | 188.45% |
| Mar 31, 2022 | 128.73% |
| Dec 31, 2021 | -219.49% |
| Sep 30, 2021 | -10.14% |